Corporate Europe Observatory

Exposing the power of corporate lobbying in the EU

  • Dansk
  • NL
  • EN
  • FI
  • FR
  • DE
  • EL
  • IT
  • NO
  • PL
  • PT
  • RO
  • SL
  • ES
  • SV

European Ombudsman demands EFSA admits failure over revolving door

Munich/ Brussels, 8 December 2011: The European Ombudsman has ruled in favour of a complaint filed by Testbiotech against the European Food Safety Authority (EFSA) regarding its approach to the 'revolving door'. The case concerns a former senior staff member at EFSA, Dr Suzy Renckens, who was head of the unit responsible for the risk assessment of genetically engineered plants for five years until 2008. Dr Renckens, a Belgian national, then moved to a job at Syngenta, a company that produces and markets these plants. The European Ombudsman has now agreed with Testbiotech's complaint and ruled that “EFSA should acknowledge that it failed to observe the relevant procedural rules and to carry out a sufficiently thorough assessment of the potential conflict of interests arising from the move of a former member of its staff to a biotechnology company”[1]. 

“The ruling from the Ombudsman shows in detail that EFSA failed to fulfill its obligations,” said Christoph Then from Testbiotech. “We are very concerned that both EFSA and the Commission have tried to deny their responsibilities in this case by rejecting our original complaints. The authority and the European Commission, which backs EFSA, are eroding confidence in European institutions. In consequence they are putting at risk the protection of consumers and the environment.”

Olivier Hoedeman from Corporate Europe Observatory said: “There have been other cases of staff going through the revolving door; EFSA should look carefully at the ruling and introduce a far stricter approach to conflicts of interest in the future. The Ombudsman makes some important recommendations which should lead to changes in how revolving door rules are implemented across the EU institutions, including at the Commission. We continue to see further scandalous revolving doors cases [2] and it is vital that the EU institutions, starting with the Commission, put improved rules and procedures in place to prevent future conflicts of interest, including a cooling off period of several years. It is time for a new start. No more business as usual.”

The Suzy Renckens case was made public by Testbiotech in November 2009 and the complaint was supported by Corporate Europe Observatory (CEO), Friends of the Earth Europe (FoEE) and Lobbycontrol (in Germany)[3]. EFSA now has until 31 March 2012 to respond to the judgement of the EU Ombudsman who has the power to table the issue in the European Parliament.

ENDS

Contact:

Testbiotech: Christoph Then, Tel +49 15154638040, info@testbiotech.org

CEO: Vicky Cann, Corporate Europe Observatory, tel: +32 28 93 09 30, mobile: +32 489 596 478

Notes:

[1] A link to the full ruling from the European Ombudsman can be found here: http://www.testbiotech.de/en/node/588

[2] CEO's RevolvingDoorWatch was launched on 7 December and it presents details of many other revolving door cases, including other cases at EFSA, and others concerning food industry lobbyists: http://www.corporateeurope.org/projects/revolvingdoorwatch

[3] All documents related to this complaint can be found here: http://www.testbiotech.de/independence

Related issues: 
 

The corporate lobby tour

CEO documents a variety of revolving door cases including a commissioner, MEPs and officials with links or interests in TTIP.
The prospective EU-US trade deal could be the world's biggest such treaty. The revolving door between public and private sectors is helping to grease the wheels of the TTIP corporate lobby.
The way in which the Commission has appointed the head of its “in-house think-tank” has demonstrated its woefully inadequate conflict of interest assessment for new appointments, says Corporate Europe Observatory. The conflict of interest assessment applied to the former chief of the Lisbon Council, Ann Mettler as head of the new European Political Strategy Center (EPSC) does not appear to have explored her close cooperation with some of the biggest corporate players in the digital and technology market. In CEO's view, this casts serious doubts on the independence of the advice that is to be given to President Juncker and his college of commissioners.
The Alliance for Lobby Transparency and Ethics Regulation (ALTER-EU) has today launched two new publications aimed at improving ethics and transparency in the European Parliament.
Policy-makers want their decisions to be based on the best available evidence; controlling the relevant science is therefore a key component of the strategy of the lobbyists who can afford it. During two days, this conference will analyse evidence politics and discuss evidence policies to find out how to make the existing EU scientific evidence appraisal system evolve towards better serving the public interest.
The European Ombudsman has opened a case on the European Commission's industry-dominated Expert Group on the risky and dangerous practice of 'fracking for natural gas.
Policy prescriptions: the firepower of the EU pharmaceutical lobby and implications for public health
A citizen's tour of corporate power in Brussels 03/09/15

Stop the Crop

Alternative Trade Mandate